IP Library Granted Patent US 8,114,979
Granted Patent B2
US 8,114,979 · App. 12/853,755 · Granted Feb 14, 2012

Di-alpha amino anthraquinone compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,114,979
App. No.
12/853,755
Granted
Feb 14, 2012
Kind
B2
Abstract

The invention provides novel anthraquinone compositions that are useful as broad-spectrum quenchers of fluorescence and provides methods for making and using them. The anthraquinone quenchers can be conjugated to a variety of biologically relevant compounds, including lipids, nucleic acids, polypeptides, and more specifically antigens, steroids, vitamins, drugs, haptens, metabolites, toxins, environmental pollutants, amino acids, peptides, proteins, nucleotides, oligonucleotides, polynucleotides, carbohydrates, and their analogs. The invention also provides kits comprising, in one or more containers, at least one anthraquinone quencher dye composition of the present invention, and instructions for using that composition.

Claims (6)

1. A compound comprising an oligonucleotide labeled with a fluorophore and quencher, wherein the oligonucleotide is adapted to hybridize to a selected nucleic acid sequence, and wherein the quencher is a di-alpha amino anthraquinone comprising a first amino group and a second amino group attached at alpha-positions of the anthraquinone, wherein fluorescence of the fluorophore is reduced by fluorescence resonance energy transfer to the quencher or by ground state quenching by the quencher when the oligonucleotide is not hybridized to the selected nucleic acid sequence.

2. The compound of claim 1 , wherein the fluorophore is selected from the group consisting of pyrene, anthracene, naphthalene, acridine, stilbene, indole, benzindole, oxazole, thiazole, benzothiazole, cyanine, carbocyanine, salicylate, anthranilate, coumarin, fluorescein and rhodamine.

3. The compound of claim 1 , wherein at least one of the first and second amino group is substituted with substituent comprising an aryl or an alkyl.

4. The compound of claim 1 , wherein fluorescence is reduced by fluorescence resonance energy transfer when the oligonucleotide is not hybridized to the selected nucleic acid sequence.

5. The compound of claim 1 , wherein fluorescence is reduced by ground state quenching when the oligonucleotide is not hybridized to the selected nucleic acid sequence.

6. The compound of claim 1 , wherein fluorescence is reduced by both fluorescence resonance energy transfer and ground state quenching when the oligonucleotide is not hybridized to the selected nucleic acid sequence.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Oct 5, 2017
From: JPMORGAN CHASE BANK, N.A.
To: INTEGRATED DNA TECHNOLOGIES, INC.
Reel/Frame 044167/0215 →
SECURITY INTEREST Recorded Feb 1, 2016
From: INTEGRATED DNA TECHNOLOGIES, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 037675/0041 →